Addressing Treatment Of Bipolar Disorder Paper

Addressing Treatment Of Bipolar Disorder Paper

Bipolar disorder presents considerable challenges to patients and healthcare providers due to its fluctuating mood episodes. Essential in its management are mood stabilizer medications like carbamazepine, lamotrigine, lithium, and valproate, which this paper extensively examines. Delving into their mechanisms of action, baseline assessment, and laboratory monitoring, alongside special population considerations and FDA approval indications, it offers insights into dosing strategies and major drug-drug interactions. Additionally, the paper discusses the ethical, legal, and social implications tied to prescribing these medications, emphasizing patient-centered care. By integrating evidence-based insights, it aims to equip clinicians with practical guidance for optimizing treatment outcomes and enhancing the quality of life for individuals with bipolar disorder.

ORDER A PLAGIARISM-FREE PAPER HERE

Carbamazepine

Carbamazepine, a traditional mood stabilizer medication, has been widely used for the treatment of bipolar disorder and related mood disorders. Carbamazepine exerts its therapeutic effects through multiple mechanisms. Primarily, it acts by blocking voltage-gated sodium channels, which stabilizes neuronal membranes and decreases the release of excitatory neurotransmitters such as glutamate (Grunze et al., 2021)Addressing Treatment Of Bipolar Disorder Paper. Additionally, carbamazepine may enhance the activity of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, contributing to its mood-stabilizing properties.

Baseline Assessment and Laboratory Considerations

Before initiating carbamazepine therapy, a comprehensive baseline assessment is essential. This should include a thorough medical history, evaluation of psychiatric symptoms, assessment of current medications, and screening for medical comorbidities. Laboratory considerations include baseline tests such as complete blood count (CBC), liver function tests (LFTs), renal function tests, and serum electrolytes. These baseline assessments help in identifying any pre-existing conditions that may impact carbamazepine therapy and establish a reference point for monitoring (Grunze et al., 2021)Addressing Treatment Of Bipolar Disorder Paper. Ongoing monitoring is crucial to ensure the safety and efficacy of carbamazepine treatment. The frequency of laboratory assessments depends on various factors, including the patient’s age, medical history, and concurrent medications. Typically, monitoring of CBC, LFTs, and serum electrolytes is recommended at regular intervals, especially during the initial phase of treatment and dose adjustments. Close monitoring allows for early detection of potential adverse effects such as hematological abnormalities, hepatic dysfunction, and electrolyte imbalances, which may necessitate dose adjustments or discontinuation of therapy.

Special Considerations When Prescribing Medicine

Special considerations are warranted when prescribing carbamazepine to certain populations: Limited data exist regarding gender differences in carbamazepine pharmacokinetics and response. However, individualized dosing and careful monitoring are recommended for all patients, regardless of gender. Elderly patients may exhibit altered pharmacokinetics due to age-related changes in metabolism and clearance (Grunze et al., 2021)Addressing Treatment Of Bipolar Disorder Paper. Lower initial doses and slower titration may be necessary to minimize the risk of adverse effects. Patients with hepatic impairment require cautious dosing and close monitoring of liver function tests, as carbamazepine is predominantly metabolized in the liver. Additionally, caution is advised in patients with renal impairment, as renal excretion of carbamazepine and its metabolites may be impaired.

FDA-approval and Typical Dosing and Therapeutic Endpoints for Psychiatric Use

Carbamazepine is FDA-approved for the treatment of various seizure disorders, including complex partial seizures and generalized tonic-clonic seizures. Additionally, it is indicated for the management of trigeminal neuralgia and acute manic or mixed episodes associated with bipolar disorder (Beydoun et al., 2020)Addressing Treatment Of Bipolar Disorder Paper. The dosing of carbamazepine for psychiatric indications varies based on individual patient factors such as age, weight, renal and hepatic function, and concomitant medications. Initial dosing is typically low to minimize the risk of adverse effects, with gradual titration to achieve therapeutic levels. Therapeutic plasma levels of carbamazepine for psychiatric use generally range from 4 to 12 µg/mL. However, optimal dosing and therapeutic endpoints should be determined based on clinical response and tolerability.

Major Drug-Drug Interaction Considerations

Carbamazepine has several significant drug-drug interactions that can impact its efficacy and safety: Co-administration of carbamazepine with lurasidone may decrease lurasidone plasma levels, potentially reducing its efficacy. Dose adjustments of lurasidone may be necessary when used concomitantly with carbamazepine. Grapefruit juice can inhibit the metabolism of carbamazepine, leading to increased serum levels and potential toxicity. Patients should be advised to avoid consuming grapefruit juice while taking carbamazepine, or alternative medications should be considered (Beydoun et al., 2020)Addressing Treatment Of Bipolar Disorder Paper. Carbamazepine may also interact with various medications metabolized through the cytochrome P450 enzyme system, including antidepressants, antipsychotics, oral contraceptives, and anticoagulants. Clinicians should carefully evaluate potential drug interactions and consider dose adjustments or alternative treatment options as needed.

Lamotrigine

Lamotrigine is a well-established mood stabilizer medication utilized in the management of bipolar disorder and related mood disorders. Lamotrigine exerts its therapeutic effects primarily by inhibiting the release of glutamate, an excitatory neurotransmitter, thereby reducing excitatory neurotransmission in the central nervous system (Pahwa et al., 2020)Addressing Treatment Of Bipolar Disorder Paper. By modulating glutamate release, lamotrigine helps stabilize mood and prevent mood swings characteristic of bipolar disorder.

Baseline Assessment and Laboratory Considerations

Before initiating lamotrigine therapy, clinicians should conduct a comprehensive baseline assessment encompassing medical history, psychiatric evaluation, medication history, and screening for relevant medical comorbidities. Baseline laboratory tests, including liver function tests (LFTs) and renal function tests, are recommended to establish a baseline and identify any pre-existing conditions that may impact treatment (Pahwa et al., 2020)Addressing Treatment Of Bipolar Disorder Paper. Regular monitoring during lamotrigine therapy is essential to ensure safety and efficacy. The frequency of laboratory assessments varies based on individual patient factors, treatment duration, and concurrent medications. Typically, monitoring of liver function and renal function is recommended periodically to detect any abnormalities early and adjust treatment accordingly.

Special Population Considerations

Special considerations should be taken into account when prescribing lamotrigine to specific populations: Elderly patients may require dose adjustments due to age-related changes in drug metabolism and clearance. Lower initial doses and slower titration may be necessary to minimize the risk of adverse effects. Patients with hepatic impairment may exhibit altered lamotrigine metabolism, necessitating dose adjustments and closer monitoring of liver function (Pahwa et al., 2020)Addressing Treatment Of Bipolar Disorder Paper. Renal excretion plays a significant role in lamotrigine elimination. Patients with renal impairment may require dosage adjustments to prevent accumulation and potential toxicity.

FDA Approval Indications, Typical Dosing, and Therapeutic Endpoints

Lamotrigine is FDA-approved for the maintenance treatment of bipolar disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in patients treated for acute mood episodes with standard therapy (Armstrong et al., 2020)Addressing Treatment Of Bipolar Disorder Paper. The dosing regimen for lamotrigine varies depending on the indication and individual patient characteristics. Initiation of lamotrigine typically involves a low initial dose, followed by gradual titration over several weeks to achieve therapeutic levels. Therapeutic endpoints for lamotrigine are not determined by plasma concentration monitoring but rather by clinical response and tolerability. Maintenance doses are generally lower than initial doses and are titrated to the lowest effective dose that maintains symptom control.

Major Drug-Drug Interaction Considerations

Lamotrigine may interact with other medications, impacting its efficacy and safety: Co-administration of lamotrigine with valproate may increase lamotrigine plasma levels due to inhibition of lamotrigine metabolism. Dose adjustments of lamotrigine may be necessary to minimize the risk of adverse effects. Rifampin, a potent inducer of cytochrome P450 enzymes, can significantly decrease lamotrigine plasma levels (Armstrong et al., 2020)Addressing Treatment Of Bipolar Disorder Paper. Dose adjustments of lamotrigine may be required when co-administered with rifampin to maintain therapeutic efficacy. Lamotrigine may also interact with other medications metabolized by cytochrome P450 enzymes, such as oral contraceptives, antidepressants, and antipsychotics. Clinicians should assess potential drug interactions and adjust doses or consider alternative treatment options as necessary.

ORDER HERE

Lithium

Lithium has been a cornerstone in the treatment of bipolar disorder for decades. The exact mechanism of lithium’s mood-stabilizing effects is not fully understood, but it is thought to involve the modulation of neurotransmitter signaling pathways, including serotonin and norepinephrine (Vecera et al., 2021)Addressing Treatment Of Bipolar Disorder Paper. Lithium may also influence intracellular signaling cascades, leading to changes in neuronal function and gene expression. Additionally, lithium may exert neuroprotective effects by reducing excitotoxicity and oxidative stress in the brain.

Baseline Assessment and Laboratory Considerations

Before initiating lithium therapy, a comprehensive baseline assessment is essential. This should include a thorough medical history, psychiatric evaluation, assessment of mood symptoms, and screening for relevant medical comorbidities. Laboratory considerations encompass baseline tests such as serum lithium levels, renal function tests (e.g., serum creatinine, estimated glomerular filtration rate), thyroid function tests (e.g., thyroid-stimulating hormone, free thyroxine), and electrolyte levels (e.g., serum sodium). These baseline assessments establish a reference point for monitoring and help identify any pre-existing conditions that may impact lithium therapy. Ongoing monitoring is crucial to ensure the safety and efficacy of lithium treatment (Vecera et al., 2021)Addressing Treatment Of Bipolar Disorder Paper. The frequency of laboratory assessments depends on various factors, including the patient’s age, renal function, concurrent medications, and duration of therapy. Regular monitoring of serum lithium levels is essential to maintain therapeutic concentrations and prevent toxicity. Additionally, monitoring of renal function, thyroid function, and electrolyte levels helps detect potential adverse effects such as lithium-induced nephrotoxicity, hypothyroidism, and electrolyte imbalances.

Special Population Considerations

Special considerations should be taken into account when prescribing lithium to specific populations: Elderly patients may exhibit altered lithium pharmacokinetics due to age-related changes in renal function. Lower initial doses and slower titration may be necessary to minimize the risk of lithium toxicity (Vecera et al., 2021). Lithium is predominantly excreted unchanged by the kidneys. Patients with renal impairment are at increased risk of lithium accumulation and toxicity. Dose adjustments are required based on the degree of renal impairment, and regular monitoring of renal function and serum lithium levels is essential. Lithium can interfere with thyroid function, leading to hypothyroidism or exacerbation of pre-existing thyroid disorders (Vecera et al., 2021)Addressing Treatment Of Bipolar Disorder Paper. Thyroid function should be monitored regularly, and thyroid hormone replacement therapy may be required in patients with lithium-induced hypothyroidism. Lithium is FDA-approved for the treatment of acute mania associated with bipolar disorder and for the maintenance treatment of bipolar disorder to prevent the recurrence of mood episodes (mania, hypomania, depression, mixed episodes).

Typical Dosing and Therapeutic

The dosing regimen for lithium varies based on individual patient factors and treatment goals. Lithium is typically initiated at a low dose and titrated gradually to achieve therapeutic serum lithium levels (Vecera et al., 2021)Addressing Treatment Of Bipolar Disorder Paper. Therapeutic lithium levels for acute mania typically range from 0.8 to 1.2 milliequivalents per liter (mEq/L), while maintenance levels are generally lower, ranging from 0.6 to 1.0 mEq/L. Optimal dosing and therapeutic endpoints should be determined based on clinical response, tolerability, and serum lithium levels.

Major Drug-Drug Interaction Considerations

Lithium has several significant drug-drug interactions that can impact its efficacy and safety: Co-administration of lithium with furosemide can increase lithium reabsorption in the renal tubules, leading to elevated serum lithium levels and potential toxicity. Close monitoring of serum lithium levels and renal function is essential, and dose adjustments of lithium may be required. Lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, can decrease lithium clearance, resulting in increased serum lithium levels (Vecera et al., 2021). Regular monitoring of serum lithium levels and renal function is recommended when co-administering lithium with lisinopril, and dose adjustments may be necessary. Lithium may interact with various medications metabolized by cytochrome P450 enzymes, such as selective serotonin reuptake inhibitors (SSRIs), nonsteroidal anti-inflammatory drugs (NSAIDs), and diuretics. Clinicians should assess potential drug interactions and adjust doses or consider alternative treatment options as needed.

Valproate in the Treatment of Bipolar Disorder

Valproate, a broad-spectrum antiepileptic medication, has been widely used as a mood stabilizer in the treatment of bipolar disorder. Valproate’s mechanism of action in mood stabilization is multifaceted. It enhances the activity of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, leading to increased GABAergic neurotransmission and inhibition of neuronal excitability (Natale et al., 2023)Addressing Treatment Of Bipolar Disorder Paper. Additionally, valproate may modulate voltage-gated sodium channels and inhibit the activity of excitatory neurotransmitters such as glutamate, further contributing to its mood-stabilizing effects.

Baseline Assessment, Laboratory Considerations

Before initiating valproate therapy, a comprehensive baseline assessment is essential. This should include a thorough medical history, psychiatric evaluation, assessment of mood symptoms, and screening for relevant medical comorbidities. Laboratory considerations encompass baseline tests such as complete blood count (CBC), liver function tests (LFTs), serum valproate levels, and serum ammonia levels. These baseline assessments help establish a reference point for monitoring and identifying any pre-existing conditions that may impact valproate therapy. Ongoing monitoring is crucial to ensure the safety and efficacy of valproate treatment (Natale et al., 2023)Addressing Treatment Of Bipolar Disorder Paper. The frequency of laboratory assessments depends on various factors, including the patient’s age, medical history, concurrent medications, and duration of therapy. Regular monitoring of CBC, LFTs, serum valproate levels, and serum ammonia levels is recommended to detect potential adverse effects such as hematological abnormalities, hepatic dysfunction, and hyperammonemia. Additionally, monitoring for signs of hepatotoxicity, pancreatitis, and other serious adverse reactions is essential for early detection and management.

Special Population Considerations

Special considerations should be taken into account when prescribing valproate to specific populations: Valproate use is associated with an increased risk of teratogenicity and adverse neurodevelopmental outcomes in offspring exposed during pregnancy. Women of childbearing age should receive comprehensive counseling regarding the risks and benefits of valproate therapy, and effective contraception should be used to prevent pregnancy (Natale et al., 2023). Elderly patients may exhibit altered valproate pharmacokinetics due to age-related changes in drug metabolism and clearance. Lower initial doses and slower titration may be necessary to minimize the risk of adverse effects. Valproate is predominantly metabolized in the liver, and patients with hepatic impairment are at increased risk of hepatotoxicity. Close monitoring of liver function is essential, and dose adjustments may be required in patients with hepatic impairment. Valproate is FDA-approved for the treatment of acute mania associated with bipolar disorder and for the maintenance treatment of bipolar disorder to prevent the recurrence of mood episodes (mania, hypomania, depression, mixed episodes)Addressing Treatment Of Bipolar Disorder Paper.

Typical Dosing and Therapeutic Endpoints

The dosing regimen for valproate varies based on individual patient factors and treatment goals. Valproate is typically initiated at a low dose and titrated gradually to achieve therapeutic serum levels. Therapeutic serum valproate levels for the treatment of bipolar disorder generally range from 50 to 125 micrograms per milliliter (µg/mL) (Natale et al., 2023). Optimal dosing and therapeutic endpoints should be determined based on clinical response, tolerability, and serum valproate levels.

Major Drug-Drug Interaction Considerations

Valproate has several significant drug-drug interactions that can impact its efficacy and safety: Co-administration of valproate with estrogen-containing birth control may increase valproate plasma levels, leading to enhanced pharmacological effects and an increased risk of adverse effects. Patients should be advised to use alternative contraceptive methods or consider dose adjustments of valproate (Natale et al., 2023)Addressing Treatment Of Bipolar Disorder Paper. Valproate may increase serum concentrations of amitriptyline, a tricyclic antidepressant, leading to enhanced pharmacological effects and an increased risk of adverse reactions. Close monitoring of amitriptyline levels and clinical response is recommended when co-administering valproate with amitriptyline. Valproate may interact with various medications metabolized by cytochrome P450 enzymes, such as antipsychotics, antidepressants, and anticoagulants. Clinicians should assess potential drug interactions and adjust doses or consider alternative treatment options as needed.

Ethical Considerations

Prescribing therapy for bipolar and related mood disorders entails navigating various ethical, legal, and social considerations. Ethically, clinicians must prioritize patient autonomy, informed consent, and beneficence, ensuring that treatment decisions align with patients’ values and preferences (Harris et al., 2021)Addressing Treatment Of Bipolar Disorder Paper. Legally, adherence to regulatory guidelines, including informed consent procedures and documentation, is imperative to mitigate liability risks. Socially, addressing stigma surrounding mental health treatment and promoting awareness and acceptance play crucial roles in fostering a supportive environment for patients. Additionally, considerations such as access to care, cultural competence, and socioeconomic factors influence treatment outcomes and warrant attention to promote equity in mental healthcare delivery.

References

Armstrong, A. G., Kalia, R., & Troutman, M. (2022). Lamotrigine Drug Interactions: Ignorance is not Bliss. Kansas Journal of Medicine, 15, 109. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942395/

Beydoun, A., DuPont, S., Zhou, D., Matta, M., Nagire, V., & Lagae, L. (2020). Current role of carbamazepine and oxcarbazepine in the management of epilepsy. Seizure, 83, 251-263. https://doi.org/10.1016/j.seizure.2020.10.018

Grunze, A., Amann, B. L., & Grunze, H. (2021). Efficacy of carbamazepine and its derivatives in the treatment of bipolar disorder. Medicina, 57(5), 433. Addressing Treatment Of Bipolar Disorder Paper https://doi.org/10.3390/medicina57050433

Harris, J. I., Hanson, D., Leskela, J., Billig, J., Padilla-Martinez, V., Boyd, J., & Nienow, T. (2021). Reconsidering research exclusion for serious mental illness: ethical principles, current status, and recommendations. Journal of Psychiatric Research, 143, 138-143. https://doi.org/10.1016/j.jpsychires.2021.09.016

Natale, G., Fini, E., Calabrò, P. F., Carli, M., Scarselli, M., & Bocci, G. (2023). Valproate and lithium: Old drugs for new pharmacological approaches in brain tumors?. Cancer Letters, 216125. https://doi.org/10.1016/j.canlet.2023.216125

Pahwa, M., Nuñez, N. A., Joseph, B., Seshadri, A., Gerberi, D. J., Frye, M. A., & Singh, B. (2020). Efficacy and tolerability of lamotrigine in borderline personality disorder: a systematic review and meta-analysis. Psychopharmacology bulletin, 50(4), 118. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7511148/

Tondelli, M., Vaudano, A. E., Sisodiya, S. M., & Meletti, S. (2020). Valproate use is associated with posterior cortical thinning and ventricular enlargement in epilepsy patients. Frontiers in neurology, 11, 549819. https://doi.org/10.3389/fneur.2020.00622

Vecera, C. M., Fries, G. R., Shahani, L. R., Soares, J. C., & Machado-Vieira, R. (2021). Pharmacogenomics of lithium response in bipolar disorder. Pharmaceuticals, 14(4), 287. https://doi.org/10.3390/ph14040287 Addressing Treatment Of Bipolar Disorder Paper

NURS 6630N WEEK 8 ASSIGNMENT INSTRUCTIONS
TOPIC: MOOD STABILIZER

This Assignment is designed to help you analyze the many considerations for prescribing mood stabilizers, as well as organizing the many different lab components to consider when prescribing to a patient.
TO PREPARE
• Review the Required Learning Resources.
• Review indications and considerations for traditional mood stabilizer psychopharmacology treatments, including carbamazepine, lamotrigine, lithium, and valproate products.

LEARNING RESOURCES:
• Goldin, D. S. (2023). Fast facts for psychopharmacology for nurse practitioners. Springer Publishing.
o Chapter 8, “Mood Stabilizers “(pp. 150—178)
• American Psychiatric Association. (2010). Practice guideline for the treatment of patients with bipolar disorderLinks to an external site. (2nd ed.). APA. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/bipolar.pdf
• comLinks to an external site.. (2023). https://www.drugs.com/
Note: Please use the following resource to check the most up-to-date box warnings, FDA approvals and indications, recommendations for follow-up evaluations, changes, etc.
• Approved Medications for Bipolar and Related Mood Disorders
Note: Utilize the following medication table to familiarize yourself with the medications aligned with the topics presented this week.
Lithium Valproate Lamotrigine Carbamazepine Lurasidone
Aripiprazole Cariprazine Lumateperone Quetiapine Risperidone
Olanzapine Ziprasidone Asenapine Addressing Treatment Of Bipolar Disorder Paper

ORDER TODAY

THE ASSIGNMENT
Construct a 5- to 6-page paper discussing each of the four traditional mood stabilizer medications: carbamazepine, lamotrigine, lithium, and valproate products. Support your answers with five (5) evidence-based, peer-reviewed scholarly literature.
Note: APA style format will apply.
Your paper should include the following for each:
• Proposed mechanism of action
• Baseline assessment, laboratory considerations, and frequency of ongoing labs and assessments
Note: Discuss the importance of assessment and labs.
• Special population considerations (birth assigned gender, age, other medical comorbidity considerations)
• FDA approval indications
• Typical dosing with discussion on therapeutic endpoints for psychiatric use
• Major drug–drug interaction considerations
o For each of these medications, please review potential drug–drug interactions listed below. Consider alternative dosing schedules, clinical implications for the drug interactions, additional patient education needed, any additional monitoring recommended, or collaboration needed with other medical professions (such as, primary care providers)Addressing Treatment Of Bipolar Disorder Paper
 Lamotrigine + Valproate
 Lamotrigine + Rifampin
 Valproate + Estrogen containing birth control.
 Valproate + Amitriptyline
 Lithium + Furosemide
 Lithium + Lisinopril
 Carbamazepine + Lurasidone
 Carbamazepine + Grapefruit juice
o Discuss the ethical, legal, and social implications related to prescribing bipolar and other related mood-disorder diagnoses therapy for patients.
Reminder: The College of Nursing requires that all papers submitted include a title page, introduction, summary, and references. For this Assignment, you are only required to include a title page. The Walden Writing Center Sample PaperLinks to an external site. provides an example of those required elements.

NOTE BELOW: Addressing Treatment Of Bipolar Disorder Paper
Students who use subheadings/paragraphs in their posts get better grades.
PLEASE USE SUBHEADINGS/PARAGRAGHS

NURS_6630_Week8_Assignment_Rubric
NURS_6630_Week8_Assignment_Rubric
Criteria Ratings Pts
This criterion is linked to a Learning OutcomeFor each of the four (4) traditional mood stabilizers, response includes proposed mechanism of action, baseline assessment, laboratory considerations, and frequency of ongoing. Discusses the importance of assessment and labs. Indication of special population considerations FDA approval. Discusses typical dosing with focus on therapeutic endpoints for psychiatric use of major drug-drug interaction considerations. 50 to >36.0 pts
Excellent
The response comprehensively and clearly describes all of the elements for each of the four (4) mood stabilizers. 36 to >24.0 pts Addressing Treatment Of Bipolar Disorder Paper
Good
The response clearly describes at least 75% the Assignment elements for three to four (3–4) mood stabilizers. 24 to >11.0 pts
Fair
The response describes at least 50% the Assignment elements for each mood stabilizer or only two (2) mood stabilizers discussed. 11 to >0 pts
Poor
The response includes inaccurate and vague examples that describe 25% or less of the Assignment elements for one (1) mood stabilizer, or some or all are missing.
50 pts
This criterion is linked to a Learning OutcomeReviews the potential drug–drug interactions of the following: *Lamotrigine + Valproate; *Lamotrigine + Rifampin; *Valproate + Estrogen containing birth control; *Valproate + Amitriptyline; *Lithium + Furosemide; *Lithium + Lisinopril; *Carbamazepine + Lurasidone; *Carbamazepine + Grapefruit juice. Consider alternative dosing schedules, clinical implications for the drug interactions, additional patient education needed, any additional monitoring recommended, or collaboration needed with other medical professions. 20 to >18.0 pts
Excellent
Reviews all seven (7) of the potential drug–drug interactions with clear and accurate Discussion of alternative dosing, patient education, monitoring recommendation, and when to collaborate. 18 to >15.0 pts
Good
Reviews five to six (5–6) of the potential drug–drug interactions with clear and accurate Discussion of alternative dosing, patient education, monitoring recommendation, and when to collaborate. 15 to >10.0 pts Addressing Treatment Of Bipolar Disorder Paper
Fair
Reviews three to four (3–4) of the potential drug–drug interactions with some Discussion and minor inaccuracies of alternative dosing, patient education, monitoring recommendation, and when to collaborate. 10 to >0 pts
Poor
Reviews all seven (7) of the potential drug–drug interactions with vague and major inaccuracies noted in Discussion including alternative dosing, patient education, monitoring recommendation, and when to collaborate.
20 pts
This criterion is linked to a Learning OutcomeDiscusses ethical, legal, and social implications related to prescribing these medications to patients. 10 to >7.0 pts
Excellent
The response accurately and clearly discusses ethical, legal and social implications. The response includes relevant, specific, and appropriate examples that fully support the Discussion. 7 to >4.0 pts
Good
The response accurately discusses ethical, legal and social implications. The response includes relevant, specific, and accurate examples that support the Discussion. 4 to >1.0 pts
Fair
The response inaccurately or vaguely discusses ethical, legal and social implications. The response includes inaccurate and irrelevant examples that may support the Discussion. 1 to >0 ptsAddressing Treatment Of Bipolar Disorder Paper
Poor
The response inaccurately and vaguely discusses ethical, legal and social implications, or it is missing. The response includes inaccurate and vague examples that do not support the Discussion, or it is missing.
10 pts
This criterion is linked to a Learning OutcomeThe paper is succinct and is 5–6 pages. Five (5) evidence-based, peer- reviewed scholarly references outside of course resources. 5 to >4.0 pts
Excellent
The paper is succinct and is 5–6 pages. Five (5) evidence-based, peer- reviewed scholarly references outside of course resources 4 to >3.0 pts
Good
The paper is succinct and is 7–8 pages. Four (4) evidence-based, peer- reviewed scholarly references outside of course resources 3 to >1.0 pts
Fair
The paper is somewhat succinct and is 8–9 pages. Two or three (2 or 3) evidence-based, peer- reviewed scholarly references outside of course resources 1 to >0 pts
Poor
The paper is not succinct and is 10+ pages. One (1) or no evidence-based, peer- reviewed scholarly references outside of course resources
5 pts
This criterion is linked to a Learning OutcomeWritten Expression and Formatting—Paragraph Development and Organization: Paragraphs make clear points that support well-developed ideas, flow logically, and demonstrate continuity of ideas. Sentences are carefully focused—neither long and rambling nor short and lacking substance. A clear and comprehensive purpose statement and introduction is provided which delineates all required criteria. 5 to >4.0 pts
Excellent Addressing Treatment Of Bipolar Disorder Paper
Paragraphs and sentences follow writing standards for flow, continuity, and clarity. A clear and comprehensive purpose statement, introduction, and conclusion is provided which delineates all required criteria. 4 to >3.0 pts
Good
Paragraphs and sentences follow writing standards for flow, continuity, and clarity 80% of the time. Purpose, introduction, and conclusion of the Assignment is stated yet is brief and not descriptive. 3 to >1.0 pts
Fair
Paragraphs and sentences follow writing standards for flow, continuity, and clarity 60%–79% of the time. Purpose, introduction, and conclusion of the Assignment is vague or off topic. 1 to >0 pts
Poor
Paragraphs and sentences follow writing standards for flow, continuity, and clarity less than 60% of the time. No purpose statement, introduction, or conclusion was provided.
5 pts
This criterion is linked to a Learning OutcomeWritten Expression and Formatting—English writing standards: Correct grammar, mechanics, and proper punctuation. 5 to >4.0 pts
Excellent
Uses correct grammar, spelling, and punctuation with no errors. 4 to >3.0 pts
Good
Contains one or two grammar, spelling, and punctuation errors. 3 to >1.0 pts Addressing Treatment Of Bipolar Disorder Paper
Fair
Contains three or four grammar, spelling, and punctuation errors. 1 to >0 pts
Poor
Contains five or more grammar, spelling, and punctuation errors that interfere with the reader’s understanding.
5 pts
This criterion is linked to a Learning OutcomeWritten Expression and Formatting: The paper follows correct APA format for title page, headings, font, spacing, margins, indentations, page numbers, parenthetical/in-text citations, and reference list. 5 to >4.0 pts
Excellent
Uses correct APA format with no errors. 4 to >3.0 pts
Good
Contains one or two APA format errors. 3 to >1.0 pts
Fair
Contains three or four APA format errors. 1 to >0 pts
Poor
Contains five or more APA format errors.
5 pts
Total Points: 100 Addressing Treatment Of Bipolar Disorder Paper